Navigation Links
Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results
Date:5/3/2011

aption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including in its annual report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission on March 8, 2011.  Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

JAZZ PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited) Three Months Ended March 31,20112010 Revenues: Product sales, net

$   49,903$
34,283 Royalties, net

693605 Contract revenues

285285 Total revenues

50,88135,173 Operating expenses: Cost of product sales

2,8092,882 Selling, general and administrative

19,91116,790 Research and development

3,6956,215 Intangible asset amortization

1,8622,057 Total operating expenses

28,27727,944 Income from operations

22,6047,229 Interest income

12 Interest expense

(777)(5,767) Other expense

(1)- Net income  

$   21,827$
,464 Net income per share: Basic

$
.54$
.05 Diluted

$
.48$
.04 Weighted-average common shares used in computing   net income per share: Basic

40,36231,412 Diluted

45,69734,926 JAZZ PHARMACEUTICALS, INC. SUMMARY OF PRODUCT SALES, NET (In thousands) (Unaudited) Three Months Ended March 31,20112010Xyrem

$   42,778$
28,745Luvox CR

7,1255,538Total

$   49,903$
34,283JAZZ PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands) (Unaudited) March 31,December 31,20112010ASSETSCurrent assets:Cash and cash equivalents

$   65,061$
44,794Restricted cash

400400Accounts receivable, net of allowances

21,38322,08
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , October 1, 2014 ... Next Generation Sequencing (NGS) data analysis, today launches a ... cystic fibrosis analysis in a single NGS experiment. The ... all types of variants in a single NGS experiment ... it has not been possible to simultaneously analyse all ...
(Date:9/30/2014)... MARIETTA, Ga. , Sept. 30, 2014 ... leading regenerative medicine company utilizing human amniotic tissue and ... therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports ... Dr. Tom Koob , Ph.D., Chief Scientific Officer, ... Mesa. Dr. Koob will present on Tuesday, October 7, ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Aileron Therapeutics, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
Breaking Medicine Technology:Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2MiMedx to Present at the Stem Cell Meeting on the Mesa 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3
... At the 10th Asian Forum on Corporate Responsibility ... and its philanthropic foundation the Abbott Fund were honored ... advancing science education in the region.  Abbott Science Education ... innovative events designed to spark an interest in life-long ...
... Mass. and TORONTO, Oct. 24, 2011 Generex Biotechnology ... the Company is planning an investor update conference call ... to provide investors with an update on (i) the ... previously announced spinout of its wholly-owned immunotherapeutics subsidiary, Antigen ...
Cached Medicine Technology:Abbott Honored With Asian CSR Award for Leadership in Science Education 2Abbott Honored With Asian CSR Award for Leadership in Science Education 3Generex Announces Investor Update Conference Call Planned for Late November 2Generex Announces Investor Update Conference Call Planned for Late November 3
(Date:10/2/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... major highway may raise your risk for high blood pressure, ... women, those who lived within 109 yards of a busy ... blood pressure than women living at least half a mile ... highlight the importance of our physical environment on our health ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... the stops to rescue surgical patients in crisis are ... such heroism is questionable, a new study suggests. ... saving elderly patients with life-threatening complications after major surgery, ... senior author Dr. Amir Ghaferi. He is assistant professor ...
(Date:10/1/2014)... Adelaide have developed a model that could help to ... treatment - from their very first psychotic episode. , ... including clinical symptoms, cognitive abilities, MRI scans of the ... Speaking in the lead up to World Mental Health ... , Professor Bernhard Baune , says the model ...
(Date:10/1/2014)... study published today in the Journal of the ... than 50 years with moderate or severe chronic knee ... from the University of Melbourne randomly assigned 282 patients ... no acupuncture or sham or pretend laser treatment. ... and acupuncturists blinded to laser and sham (inactive) laser ...
(Date:10/1/2014)... PA, October 1, 2014 Patients with increased ... have a greatly increased risk of depression. For ... for chronic hepatitis C virus infection causes depression ... fatty acids, more commonly known as fish oil, ... lowering the risk of heart disease and reducing ...
Breaking Medicine News(10 mins):Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Predicting the future course of psychotic illness 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Omega-3 fatty acids may prevent some forms of depression 2
... but critics want agency to act, not wait years ... ads on television should include a toll-free phone number ... U.S. health experts suggested Friday. , The experts serve ... Drug Administration. Such phone numbers are already mandated by ...
... Workers, WASHINGTON, May 16 More than ... Portland, Oregon and,Vancouver, Washington area have ratified their ... that these workers are now covered by a,strong ... secure retirement,future," said Teamsters General President Jim Hoffa., ...
... benefit from calcitriol, an oral form , , FRIDAY, May 16 ... risk of death for people with moderate to severe chronic ... , During a two-year study of more than 1,400 ... activated vitamin D, had their overall risk of death lowered ...
... what did you,say?" is a phrase being used more ... Americans, that is 1 in 9 individuals, have,significant hearing ... rate.,Thirteen out of every 100 school age children have ... attention to this social and economic problem,is what led ...
... for May 19 at 10:15 a.m. Eastern Time, ... (TSX: RBM, OTCBB: RPBIF) today announced that S. ... at the Rodman & Renshaw,5th Annual Global Healthcare ... A live web cast of the presentation ...
... needs is more unemployed politicians - and economists, ... health care at the top of their "most-important issues" ... health care plans,advanced by any of the current presidential ... U.S. Senate Majority Leader Bill Frist., Jousting with ...
Cached Medicine News:Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3
Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe....
Bard® Channel Drain...
... Used for stone manipulation ... duct. The nitinol memory wire ... its shape following extreme torsion. ... the likelihood of mucosal damage ...
Used for serial post-operative cholangiography and the placement of a wire guide to facilitate post-operative E.R.C.P. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: